Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Volvo Car AB (publ): Contemplating new green bond issuance

Volvo Car AB (publ) ("Volvo Cars") has mandated Barclays Bank Ireland PLC, Citigroup Global Markets Europe AG, Nordea Bank Abp and Société Générale as Joint Bookrunners, to arrange a series of fixed income investor calls on 29 April 2024. A senior unsecured EUR-denominated fixed rate 6-year green bond issued under Volvo Cars’ EMTN-programme guaranteed by Volvo Car Corporation may follow, subject to market conditions. The green bond will be issued in accordance with Volvo Cars’ Green Financing Framework dated May 2023, and a second party opinion rated Dark Green has been issued by CICERO,

Comintelli Introduces New Professional Services for Competitive Intelligence

Comintelli, a leading provider of SaaS platforms for Competitive & Market Intelligence, today announced the launch of a comprehensive suite of Professional Services Packages. These services bridge the gap between strategy and execution, offering tailored support that empowers customers to maximize the value of their Competitive Intelligence (CI) initiatives.   “The need for complete CI capabilities is increasing,” says Christian Bjersér, Senior Vice President, Customer Success at Comintelli. “Businesses are recognizing the immense value of actionable insights and are seeking expert

Espiria launches a new distributing share class in response to strong performance and high demand from clients

Espiria, a part of East Capital Group, is pleased to announce the introduction of a new distributing share class in response to the exceptional performance of our Nordic Corporate Bond (NCB) fund. Surpassing expectations, within 1.5 years of inception the fund has reached an AUM (Assets Under Management) of nearly SEK 2 billion and represents almost 10% of all corporate bond flows in Sweden per Fondbolagens Förening, during this period. This new share class is designed to cater to our growing pipeline of clients and their investment needs.The new distributing share class is a unique

Genexis Group presents Q1 2024 financial report

Genexis Group’s net consolidated sales Q1 2024 were EUR 19.0 million, up by EUR 3.7 million from Q4 2023 and slightly behind the EUR 20.4 million in Q1 2023The consolidated adjusted EBITDA of Q1 was EUR 3.1 million (EUR 2.1 million Q1 2023), and the operating cash flow was positive. Operating Expenses continued to decrease during Q1, the result of the cost-reduction initiatives executed in 2023. Most of the cost synergies have now come into effect, as expected. “We see a continuous increase of our sales funnel for the year and see a large base of our smaller customers forecasting

Earnings impact of the successful listing of PPI on the Oslo Stock Exchange

Samhällsbyggnadsbolaget i Norden AB's (publ) ("SBB") associated company Public Property Invest AS ("PPI") has today been successfully listed on the Oslo Stock Exchange. The listing improved PPI's access to the capital market and is thus an important part of SBB's strategy to strengthen the group's financial position and maximise shareholder value over time. In connection with the listing, SBB transfers parts of its Norwegian portfolio to PPI. ''The listing of PPI is an important milestone in the strategic transformation that SBB is undertaking to create a decentralised group structure

SSAB and Nordec agree on deliveries of fossil-free steel

SSAB and Nordec have agreed on deliveries of fossil-free steel. Nordec will use the fossil-free steel in, for example, frame structures for buildings, façades and bridges. The agreement between SSAB and Nordec is an important step towards an efficient supply chain for fossil-free steel. SSAB aims to deliver fossil-free steel to the market in 2026 and this agreement will ensure Nordec gets the quantities of steel it needs from SSAB’s production capacity. Under the collaboration, SSAB will initially supply small quantities of fossil-free steel for the first pilot project, and in the

Nordec and SSAB agree on deliveries of fossil-free steel.

Nordec and SSAB have agreed on deliveries of fossil-free steel. Nordec will use fossil-free steel in, for example, frame structures for buildings, façades, and bridges.Nordec Group Oy press release 29.04.2024 at 09.30 EET UTC+3        Nordec and SSAB agree on deliveries of fossil-free steel. Nordec and SSAB have agreed on deliveries of fossil-free steel. Nordec will use fossil-free steel in, for example, frame structures for buildings, façades, and bridges. The agreement between Nordec and SSAB is an important step

Immunovia Publishes Interim Report for January-March 2024

January-March 2024 · Net sales, which for the quarter only included royalties, amounted to SEK 156 (520) · Net earnings amounted to KSEK -2,946 (-51,658), where exchange rate effects of KSEK 21 358 (435) had a substantial impact. · Earnings per share before and after dilution were SEK -0.07 (-2.28). · Cash Flow from operating activities amount MSEK -24.4 (39.7). · Cash and equivalents at the end of the period amounted to MSEK 51.2 (68.2). · On January 31, the Company announced that Norma Alonzo Palma had been appointed Vice President of Clinical and Medical Affairs

UPM-Kymmene Corporation: Managers’ Transactions (à Porta)

UPM-Kymmene Corporation                Managers’ Transactions                        29 April 2024 at 09:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (à Porta)  On 4 April 2024, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company's Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members' behalf, and the rest in cash. In accordance with this resolution, a total of 1,462 shares have been purchased to Martin à Porta as follows:

UPM-Kymmene Corporation: Managers’ Transactions (Maas-Brunner)

UPM-Kymmene Corporation                Managers’ Transactions                        29 April 2024 at 09:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (Maas-Brunner)  On 4 April 2024, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company's Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members' behalf, and the rest in cash. In accordance with this resolution, a total of 1,462 shares have been purchased to Melanie Maas-Brunner as

UPM-Kymmene Corporation: Managers’ Transactions (Kauppi)

UPM-Kymmene Corporation                Managers’ Transactions                        29 April 2024 at 09:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (Kauppi)  On 4 April 2024, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company's Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members' behalf, and the rest in cash. In accordance with this resolution, a total of 1,462 shares have been purchased to Piia-Noora Kauppi as follows:

UPM-Kymmene Corporation: Managers’ Transactions (Manner)

UPM-Kymmene Corporation                Managers’ Transactions                        29 April 2024 at 09:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (Manner)  On 4 April 2024, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company's Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members' behalf, and the rest in cash. In accordance with this resolution, a total of 1,462 shares have been purchased to Topi Manner as follows:   ___

UPM-Kymmene Corporation: Managers’ Transactions (Aaltonen-Forsell)

UPM-Kymmene Corporation                Managers’ Transactions                        29 April 2024 at 09:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (Aaltonen-Forsell)  On 4 April 2024, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company's Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members' behalf, and the rest in cash. In accordance with this resolution, a total of 1,462 shares have been purchased to Pia Aaltonen-Forsell

UPM-Kymmene Corporation: Managers’ Transactions (Gustafsson)

UPM-Kymmene Corporation                Managers’ Transactions                        29 April 2024 at 09:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (Gustafsson)  On 4 April 2024, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company's Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members' behalf, and the rest in cash. In accordance with this resolution, a total of 1,462 shares have been purchased to Jari Gustafsson as follows:

UPM-Kymmene Corporation: Managers’ Transactions (Oudeman)

UPM-Kymmene Corporation                Managers’ Transactions                        29 April 2024 at 09:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (Oudeman)  On 4 April 2024, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company's Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members' behalf, and the rest in cash. In accordance with this resolution, a total of 1,462 shares have been purchased to Marjan Oudeman as follows:

UPM-Kymmene Corporation: Managers’ Transactions (Ehrnrooth)

UPM-Kymmene Corporation                Managers’ Transactions                        29 April 2024 at 09:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (Ehrnrooth)  On 4 April 2024, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company's Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members' behalf, and the rest in cash. In accordance with this resolution, a total of 2,816 shares have been purchased to Henrik Ehrnrooth as follows:

UPM-Kymmene Corporation: Managers’ Transactions (Wahl)

UPM-Kymmene Corporation                Managers’ Transactions                        29 April 2024 at 09:30 EEST UPM-Kymmene Corporation: Managers’ Transactions (Wahl)  On 4 April 2024, the Annual General Meeting of UPM-Kymmene Corporation resolved that the annual base fee of the company's Board of Directors is paid in the company shares and cash so that approximately 40% is payable in the company shares to be purchased on the Board members' behalf, and the rest in cash. In accordance with this resolution, a total of 1,767 shares have been purchased to Kim Wahl as follows:   ________

Press release from Careium AB:s (publ) Annual General Meeting 2024

Careium's Annual General Meeting was held at St Gertrud Konferens, Malmö on Thursday April 25, 2024 at 1 pm. At the Annual General Meeting, the following were resolved, among other things: · to adopt the income statement and the balance sheet, and the consolidated income statement and the consolidated balance sheet for 2023; · to approve the remuneration report; · that no dividend should be distributed in accordance with the proposal from the board of directors; · to grant discharge from liability for the members of the board of directors and the Managing Directors for 2023;

Truqap recommended for EU breast cancer approval

29 April 2024 Truqap plusFaslodex recommended for approval in the EU by CHMP for patients with advanced ER-positive breast cancer Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50% vs. Faslodex standard of care in a biomarker-altered population AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been recommended for approval in the European Union (EU) for the treatment of adult patients with estrogen receptor (ER)-positive, HER2‑negative locally advanced or

BlueNord: Update on Tyra Redevelopment Project

Oslo, 29 April 2024: Reference is made to stock exchange notice published on 18 April 2024 by BlueNord ASA (“BlueNord” or the “Company”) related to the operational occurrence with the IP compressor temporarily impacting the commissioning of the new Tyra facilities during the ramp-up and testing period. Continued efforts and investigations are ongoing, however, the export volumes from Tyra II are expected to be impacted for the month of May 2024.  Currently, the duration of the testing program and commissioning plan for achieving the technical milestones and driving the ramp-up to 8,1

Invitation to Oneflow’s Q1 2024 presentation on 8 May

Press release29 April 2024 Oneflow will publish its interim report for the first quarter of 2024 on 8 May at 08:00 CET. The report will be presented in a webinar at 10:00 CET the same day. Anders Hamnes, CEO and Founder of Oneflow, and Natalie Jelveh, CFO of Oneflow, will present the report and answer questions. The presentation will be held in English. To join the conference, please register here: https://oneflow.zoom.us/webinar/register/WN_32E2s8s8QPmbbsAJlk4pmg The report and presentation will be available for download on our website here: https://oneflow.com/ir/investors/

Arctic Bioscience – Q1 2024 Operational update – Progress according to plan

Highlights Q1 2024: · The HeROPA clinical trial fully recruited in January 2024, and further development is proceeding as planned   · Available liquidity end of Q1 2024 of NOK 74,6 million · Above 90 % of the total nutra 2023-revenues already secured in 2024 via sales and received purchase orders · Strong growth in the Norwegian Romega market in Q1 2024The HeROPA clinical trial was fully recruited in January 2024. Since then, the clinical trial has progressed according to plan towards 6 months primary end points read-out in second half of 2024. “As the time for read-out is

Quarterly Update – March 2024

29 April 2024 Ashoka WhiteOak Emerging Markets Trust plc (the "Company") Quarterly Update – March 2024 The Company's factsheet as at 31 March 2024 is now available: https://awemtrust.com/factsheet/ The Company has delivered a NAV total return of 11.5% since inception to 31 March 2024, outperforming the benchmark MSCI EM1 (in sterling terms) by 359bps over the same period. Among other factors, stock selection within the small and mid-cap segment has been a key driver of this outperformance. For the first quarter of 2024, the NAV was up 3.9%, outperforming the benchmark by

There are no items matching the current filter
There are no more items matching the current filter
Back to top